Business
myLotus Fertility Product - China Update
myLotus Fertility Product - China Update.
About this update from Fortis Frontier Plc
[{"type":"text","content":"\n \nRNS Number : 6229T Concepta PLC 16 October 2017 \n\n16 October 2017 \n \nConcepta plc (\"Concepta\" or the \"Company\") \n \nmyLotus Fertility Product - China Update\n \nConcepta plc (AIM: CPT), the pioneering UK healthcare company and developer of a proprietary platform and suite of products targeted at the personalised mobile health market with a primary focus on women's fertility and specifically unexplained infertility, is pleased to announce a positive update on the launch of its proprietary myLotus product in its first international market, China. \n \nDistribution Agreements\n \nThe Company has signed an additional two 3-year exclusive distribution agreements for its myLotus fertility product with Huanzhong Biotech Ltd and Wanma Technology Co., Ltd in China. \n \nThe distribution agreement with Huanzhong Biotech Ltd will cover the province of Hebei near Beijing, while Wanma Technology Co., Ltd will cover the Shanghai area. Alongside ThinkBrio, which distributes the myLotus product to Beijing and Lianoing, these two agreements will expand Concepta's product offering in China to target a total population of 147 million people across these regions.\n\nDr Yin Hui Rong, principal investigator at the Changhai Hospital Reproductive Centre,commented on the Company's myLotus product: \"I have been impressed with the performance of myLotus. This small, hand-held device is providing results that are comparable to large laboratory equipment. It opens up the opportunity for more flexibility in large and smaller hospitals but also for the women at home.\"\n\nHospital evaluation results\n \nConcepta has completed a preliminary hospital evaluation process in China to extend the use of the Company's myLotus product into early pregnancy monitoring. Based on recent positive hospital evaluation results, the Company's new distributors, Huanzhong Biotech Ltd and Wanma Technology will be the first to target the 'early pregnancy' group alongside the 'unexplained infertility' target group. There is a total target market of 2.3 million women a year across the Hebei, Beijing, Lianoing and Shanghai areas for early pregnancy monitoring.\n \nErik Henau, CEO commenting on the Company's hospital evaluation and new distribution agreements said: \"We are delighted to add these new distributors t...